MORPHABOND ER Drug Patent Profile

When do Morphabond Er patents expire, and what generic alternatives are available?

Morphabond Er is a drug marketed by Ohemo Life and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-three patent family members in ten countries.

The generic ingredient in MORPHABOND ER is morphine sulfate. There are twenty-three drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Morphabond Er

A generic version of MORPHABOND ER was approved as morphine sulfate by HOSPIRA on September 30^th, 1992.

Summary for MORPHABOND ER

International Patents:	23
US Patents:	2
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	11
Patent Applications:	3,492
Drug Prices:	Drug price information for MORPHABOND ER
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MORPHABOND ER
DailyMed Link:	MORPHABOND ER at DailyMed

See drug prices for MORPHABOND ER

Paragraph IV (Patent) Challenges for MORPHABOND ER

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MORPHABOND ER	Extended-release Tablets	morphine sulfate	15 mg, 30 mg, 60 mg and 100 mg	206544	1	2019-01-28

US Patents and Regulatory Information for MORPHABOND ER

MORPHABOND ER is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ohemo Life	MORPHABOND ER	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	206544-001	Oct 2, 2015		DISCN	Yes	No			Y
Ohemo Life	MORPHABOND ER	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	206544-004	Oct 2, 2015		DISCN	Yes	No			Y
Ohemo Life	MORPHABOND ER	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	206544-002	Oct 2, 2015		DISCN	Yes	No			Y
Ohemo Life	MORPHABOND ER	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	206544-004	Oct 2, 2015		DISCN	Yes	No			Y
Ohemo Life	MORPHABOND ER	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	206544-001	Oct 2, 2015		DISCN	Yes	No			Y

International Patents for MORPHABOND ER

See the table below for patents covering MORPHABOND ER around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2923102	MEDICAMENTS RESISTANT AUX ABUS, PROCEDES D'UTILISATION ET DE FABRICATION (ABUSE RESISTANT DRUGS, METHOD OF USE AND METHOD OF MAKING)
Australia	2015200009	Abuse resistant drugs, method of use and method of making
Japan	2016138126	乱用抵抗性医薬組成物、その使用方法および作製方法 (ABUSE RESISTANT PHARMACEUTICAL COMPOSITIONS, METHOD OF USING AND PRODUCING THEREOF)
Poland	2187873
Australia	2017200414	Abuse resistant drugs, method of use and method of making

MORPHABOND ER Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for MORPHABOND ER

Introduction to MORPHABOND ER

MORPHABOND ER is an extended-release opioid formulation indicated for the management of severe pain that requires daily, around-the-clock, long-term opioid treatment. It is formulated with SentryBond abuse-deterrent technology to mitigate the risks of misuse and abuse[1][5].

Indications and Usage

MORPHABOND ER is specifically designed for patients who require continuous opioid therapy and for whom alternative treatment options are inadequate. It is not intended for as-needed (prn) analgesia and should be reserved for patients who have not responded to other opioid or non-opioid treatments[1].

Market Size and Growth of the Opioids Market

The global opioids market was valued at approximately $22.74 billion in 2023 and is projected to grow to around $26.78 billion by 2034, with a compound annual growth rate (CAGR) of 1.5% from 2024 to 2034. This growth is driven by the increasing demand for effective pain management solutions, particularly in post-surgical, severe trauma, and cancer treatment settings[3].

Regional Market Share

North America currently holds the highest market share of the global opioids market, accounting for 45.13% in 2023. However, the Asia-Pacific region is expected to expand at the fastest CAGR during the forecast period, presenting significant growth opportunities for opioid products like MORPHABOND ER[3].

Application and Route of Administration

The pain relief segment dominates the opioids market, with a major market share of 24% in 2023. MORPHABOND ER, being an oral extended-release opioid, falls under the oral segment, which is anticipated to expand at a CAGR of 2.5% over the predicted period. The oral administration route is critical in managing severe pain and addressing respiratory distress across various care settings[3].

Abuse-Deterrent Formulations

MORPHABOND ER is one of the abuse-deterrent formulation extended-release opioid products. These formulations are designed to deter misuse by making the substances difficult to crush, chew, gel, or dissolve. This technology is a key differentiator in the market, as it addresses the critical issue of opioid abuse and misuse[5].

Prescription and Dispensing Data

According to postmarketing analysis, MORPHABOND ER had relatively low prescription numbers compared to other extended-release opioids. In 2020, it accounted for 60,000 prescriptions and 87,000 morphine equivalent grams dispensed. This data indicates that while MORPHABOND ER is not as widely prescribed as some other opioids, it still maintains a niche in the market for patients requiring abuse-deterrent formulations[4].

Competitive Landscape

The opioids market is highly competitive, with several other abuse-deterrent formulations available, such as Xtampza ER, OxyContin, Hysingla ER, and Embeda. MORPHABOND ER competes in this space by offering a unique combination of extended-release pain management and abuse-deterrent properties[4][5].

Financial Trajectory

Given the growing demand for opioids and the specific need for abuse-deterrent formulations, MORPHABOND ER is positioned to contribute to the financial growth of its manufacturers. Daiichi Sankyo, one of the companies involved in the development and marketing of MORPHABOND ER, has emphasized the importance of this product in their portfolio, particularly in their efforts to address unmet medical needs and improve patient safety[2].

Challenges and Opportunities

Despite its potential, MORPHABOND ER faces challenges such as stringent regulatory requirements and the need for careful patient selection due to the risks associated with opioid use. However, the increasing awareness of opioid abuse and the regulatory push for abuse-deterrent formulations present opportunities for growth. As healthcare providers and regulatory bodies continue to seek safer opioid options, products like MORPHABOND ER are likely to see increased adoption[1][5].

Distribution Channels

The retail pharmacy segment leads the market in terms of distribution channels, with a maximum market share of 38% in 2023. MORPHABOND ER, being available through these channels, benefits from this widespread distribution network, ensuring accessibility for patients who need it[3].

Future Outlook

As the opioids market continues to evolve, the demand for effective and safe pain management solutions is expected to drive the growth of products like MORPHABOND ER. With advancements in pharmacokinetics and patient-centric treatment approaches, the oral segment, in particular, is poised for substantial growth. This trend suggests a positive financial trajectory for MORPHABOND ER as it addresses the critical needs of patients and healthcare providers alike[3].

Key Takeaways

• Market Growth: The global opioids market is expected to grow to $26.78 billion by 2034.
• Abuse-Deterrent Technology: MORPHABOND ER's abuse-deterrent formulation is a key differentiator.
• Regional Opportunities: Asia-Pacific region is expected to expand at the fastest CAGR.
• Competitive Landscape: MORPHABOND ER competes with other abuse-deterrent opioids.
• Financial Potential: Positioned for growth due to increasing demand for safe opioid options.
• Distribution: Widely available through retail pharmacies.

FAQs

Q: What is MORPHABOND ER indicated for?

MORPHABOND ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate[1].

Q: What is the abuse-deterrent technology in MORPHABOND ER?

MORPHABOND ER is formulated with SentryBond abuse-deterrent technology, which makes the substance difficult to crush, chew, gel, or dissolve[5].

Q: How does MORPHABOND ER compare to other opioids in terms of prescriptions?

MORPHABOND ER had relatively low prescription numbers compared to other extended-release opioids, with 60,000 prescriptions in 2020[4].

Q: What is the expected growth rate of the opioids market?

The global opioids market is expected to grow at a CAGR of 1.5% from 2024 to 2034[3].

Q: Which region is expected to expand the fastest in the opioids market?

The Asia-Pacific region is expected to expand at the fastest CAGR during the forecast period[3].

Cited Sources

1. Drugs.com: MORPHABOND ER: Package Insert / Prescribing Information.
2. Daiichi Sankyo Group Value Report 2019.
3. Biospace: Opioids Market Size to Worth Around USD 26.78 Billion by 2034.
4. Pain Medicine: Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza ER.
5. MedCentral: Demystifying Opioid Abuse-Deterrent Technologies.